顶部联系方式

Time of issue:2019-09-22 00:00:00
EN
SEARCH
Confirm
Cancel

EVENTS

LEAST NEWS

Bexarotene - Potential COVID-19 treatments with recent research
Bexarotene - Potential COVID-19 treatments with recent research
2020-06-29
Since the outbreak of the Coronavirus Disease 2019(COVID-19), many parties around the world are looking for the effective drugs to treat the disease. The latest research found that Bexarotene showed significant efficacy in the COVID-19 treatment.

A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.

Article:Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
See more information
Since the outbreak of the Coronavirus Disease 2019(COVID-19), many parties around the world are looking for the effective drugs to treat the disease. The latest research found that Bexarotene showed significant efficacy in the COVID-19 treatment.

A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.

Article:Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
Effect of Ruxolitinib phosphate on COVID-19
Effect of Ruxolitinib phosphate on COVID-19
2020-06-22
April 2, 2020, Novartis announces plan to initiate clinical study of Ruxolitinib in severe COVID-19 patients and establish international compassionate use program. Patients with COVID-19 can lead to life-threatening respiratory complications due to cytokine storm. Pre-clinical and preliminary clinical evidence suggests Ruxolitinib could reduce the cytokine storm syndromes. In Italy, 7 severe COVID-19 patients in ICU accept Ruxolitinib treatment and getting better, after two days treatment, 5 patients do not need ventilator anymore.

In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.

Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.
See more information
April 2, 2020, Novartis announces plan to initiate clinical study of Ruxolitinib in severe COVID-19 patients and establish international compassionate use program. Patients with COVID-19 can lead to life-threatening respiratory complications due to cytokine storm. Pre-clinical and preliminary clinical evidence suggests Ruxolitinib could reduce the cytokine storm syndromes. In Italy, 7 severe COVID-19 patients in ICU accept Ruxolitinib treatment and getting better, after two days treatment, 5 patients do not need ventilator anymore.

In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.

Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.

FOCUS ON

FOCUS ON

Time of issue:2020-05-28 00:00:00

Huapont Pharm has been focusing on retinoids since start-up of its business, and are proud of a lot of experts with rich developing and manufacturing experiences.

 

We manufacturing APIs including:

● First generation:

  Tretinoin(Retinoic acid), Isotretinoin and Alitretinoin

● Second generation:

  Etretinate,Acitretin

● Third generation:

  Adapalene, Bexarotene and Tazarotene

 

We also manufacture Tretinoin cream, Isotretinoin soft capsules, Acitretin capsules, Adapalene cream and Tazarotene cream/gel.

NEW PLANT

NEW PLANT

Time of issue:2020-05-28 00:00:00

A now finished product plant of Huapont Pharm will be put in use in 2018, covering an area about 113516 m2 and total construction area more than 180000 m2. The new plant is designed to comply with EU GMP with a total investment of billion RMB

With a 5-times capacity increment by comparing the current plant, the new plant has 7 production lines which can manufacture:

 

25 million units for external preparations,

35 million units for external preparations(hormones),

2 billion units for tablets.

0.6 billion units for hard capsules,

7.2 million units for small volume injections

50 million units for oral solution

25 million units for soft capsules.

Bangbang Bird

QUICK LINKS

Quick Links

Time of issue:2020-05-28 00:00:00

CONTACT INFO

Contact Info

Time of issue:2020-05-28 00:00:00

TEL: +86-23-67886927

TEL: +86-23-67886928

EMAIL: api@huapont.cn

ADD.: No.69 Xingguang Avenue, Renhe Town, Yubei District,Chongqing, China 401121

FEEDBACK

留言应用名称:
feedback
Description:
验证码

地址版权

Time of issue:2019-09-22 00:00:00

© 2020 Chongqing Huapont Pharmaceutical Co., Ltd. All Rights Reserved. Powered by: www.300.cn 渝ICP备05003324号

手机版地址版权

Time of issue:2019-09-22 00:00:00

© 2020 Chongqing Huapont Pharmaceutical Co., Ltd.

Powered by: www.300.cn 渝ICP备05003324号